ArticleEClinicalMedicine2021

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.

Nicolas Bertrand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.